| Biomarker ID | 670 |
| PMID | 21647377 |
| Year | 2011 |
| Biomarker | miR-145 |
| Biomarker Basis | Expression Based |
| Biomolecule | miRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in Bone Metastatis: 17.3 fold |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(miR-145):- positive regulation of transcription by RNA polymerase II; DNA-binding transcription activator activity, RNA polymerase II-specific; positive regulation of gene expression; Pancreatic adenocarcinoma pathway; positive regulation of cell population proliferation |
| Experiment | Primary vs Bone Metastatis |
| Type of Biomarker | Prognostic |
| Cohort | Samples of 16 primary PCa and 13 bone metastases were selected for analysis |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.014 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | miR-145 |